Logo image of SURG

SURGEPAYS INC (SURG) Stock Fundamental Analysis

NASDAQ:SURG - Nasdaq - US86882L2043 - Common Stock - Currency: USD

2.72  -0.11 (-3.89%)

After market: 2.7 -0.02 (-0.74%)

Fundamental Rating

2

Taking everything into account, SURG scores 2 out of 10 in our fundamental rating. SURG was compared to 21 industry peers in the Wireless Telecommunication Services industry. While SURG seems to be doing ok healthwise, there are quite some concerns on its profitability. SURG is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SURG has reported negative net income.
In the past year SURG has reported a negative cash flow from operations.
SURG had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: SURG reported negative operating cash flow in multiple years.
SURG Yearly Net Income VS EBIT VS OCF VS FCFSURG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -190.73%, SURG is doing worse than 95.24% of the companies in the same industry.
SURG's Return On Equity of -298.57% is on the low side compared to the rest of the industry. SURG is outperformed by 90.48% of its industry peers.
Industry RankSector Rank
ROA -190.73%
ROE -298.57%
ROIC N/A
ROA(3y)-47.87%
ROA(5y)-71.76%
ROE(3y)-79.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SURG Yearly ROA, ROE, ROICSURG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SURG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SURG Yearly Profit, Operating, Gross MarginsSURG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

More info and screens

4

2. Health

2.1 Basic Checks

SURG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SURG has been increased compared to 1 year ago.
The number of shares outstanding for SURG has been increased compared to 5 years ago.
The debt/assets ratio for SURG is higher compared to a year ago.
SURG Yearly Shares OutstandingSURG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
SURG Yearly Total Debt VS Total AssetsSURG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -2.18, we must say that SURG is in the distress zone and has some risk of bankruptcy.
SURG's Altman-Z score of -2.18 is on the low side compared to the rest of the industry. SURG is outperformed by 85.71% of its industry peers.
SURG has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of SURG (0.15) is better than 95.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -2.18
ROIC/WACCN/A
WACC8.84%
SURG Yearly LT Debt VS Equity VS FCFSURG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 2.95 indicates that SURG has no problem at all paying its short term obligations.
SURG has a better Current ratio (2.95) than 100.00% of its industry peers.
SURG has a Quick Ratio of 2.66. This indicates that SURG is financially healthy and has no problem in meeting its short term obligations.
SURG has a better Quick ratio (2.66) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 2.66
SURG Yearly Current Assets VS Current LiabilitesSURG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for SURG have decreased strongly by -268.35% in the last year.
SURG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -55.61%.
SURG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.83% yearly.
EPS 1Y (TTM)-268.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-636.84%
Revenue 1Y (TTM)-55.61%
Revenue growth 3Y6.01%
Revenue growth 5Y18.83%
Sales Q2Q%-70.3%

3.2 Future

The Earnings Per Share is expected to grow by 49.07% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 67.58% on average over the next years. This is a very strong growth
EPS Next Y97.17%
EPS Next 2Y49.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year60.05%
Revenue Next 2Y67.58%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SURG Yearly Revenue VS EstimatesSURG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
SURG Yearly EPS VS EstimatesSURG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SURG. In the last year negative earnings were reported.
Also next year SURG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SURG Price Earnings VS Forward Price EarningsSURG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SURG Per share dataSURG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as SURG's earnings are expected to grow with 49.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.07%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SURG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURGEPAYS INC

NASDAQ:SURG (5/2/2025, 8:24:37 PM)

After market: 2.7 -0.02 (-0.74%)

2.72

-0.11 (-3.89%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupTelecommunication Services
GICS IndustryWireless Telecommunication Services
Earnings (Last)03-25 2025-03-25/amc
Earnings (Next)05-19 2025-05-19/amc
Inst Owners10.05%
Inst Owner Change0%
Ins Owners31.04%
Ins Owner Change-0.73%
Market Cap55.52M
Analysts80
Price Target6.89 (153.31%)
Short Float %5.28%
Short Ratio0.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-236.21%
Min EPS beat(2)-304.04%
Max EPS beat(2)-168.38%
EPS beat(4)0
Avg EPS beat(4)-337.76%
Min EPS beat(4)-824.37%
Max EPS beat(4)-54.25%
EPS beat(8)3
Avg EPS beat(8)-8.82%
EPS beat(12)4
Avg EPS beat(12)-69.12%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-15.73%
Min Revenue beat(2)-45.89%
Max Revenue beat(2)14.43%
Revenue beat(4)2
Avg Revenue beat(4)-6.63%
Min Revenue beat(4)-45.89%
Max Revenue beat(4)14.43%
Revenue beat(8)2
Avg Revenue beat(8)-7.49%
Revenue beat(12)4
Avg Revenue beat(12)-6.74%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)17.39%
PT rev (3m)17.39%
EPS NQ rev (1m)-27.27%
EPS NQ rev (3m)-75%
EPS NY rev (1m)60%
EPS NY rev (3m)21.21%
Revenue NQ rev (1m)-4.91%
Revenue NQ rev (3m)-4.91%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)0.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.91
P/FCF N/A
P/OCF N/A
P/B 3.62
P/tB 5.27
EV/EBITDA N/A
EPS(TTM)-2.34
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS2.98
BVpS0.75
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -190.73%
ROE -298.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.87%
ROA(5y)-71.76%
ROE(3y)-79.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover2.54
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.1%
Cap/Sales 0.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 2.66
Altman-Z -2.18
F-Score2
WACC8.84%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-268.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-636.84%
EPS Next Y97.17%
EPS Next 2Y49.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-55.61%
Revenue growth 3Y6.01%
Revenue growth 5Y18.83%
Sales Q2Q%-70.3%
Revenue Next Year60.05%
Revenue Next 2Y67.58%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-321.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year113.66%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-312.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-307.15%
OCF growth 3YN/A
OCF growth 5YN/A